Novus Therapeutics (NVUS) Upgraded by ValuEngine to Sell

ValuEngine upgraded shares of Novus Therapeutics (NASDAQ:NVUS) from a strong sell rating to a sell rating in a research note published on Monday, April 2nd.

Separately, Ascendiant Capital Markets began coverage on Novus Therapeutics in a research report on Tuesday, February 13th. They set a buy rating and a $7.00 price objective on the stock.

How to Become a New Pot Stock Millionaire

NVUS stock remained flat at $$5.00 during midday trading on Monday. The company’s stock had a trading volume of 7,284 shares, compared to its average volume of 54,044. Novus Therapeutics has a fifty-two week low of $3.12 and a fifty-two week high of $6.60.

An institutional investor recently bought a new position in Novus Therapeutics stock. Vanguard Group Inc. bought a new stake in shares of Novus Therapeutics (NASDAQ:NVUS) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 42,803 shares of the biopharmaceutical company’s stock, valued at approximately $251,000. Vanguard Group Inc. owned about 5.78% of Novus Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 32.79% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Novus Therapeutics (NVUS) Upgraded by ValuEngine to Sell” was originally reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2018/04/18/novus-therapeutics-nvus-upgraded-by-valuengine-to-sell.html.

Novus Therapeutics Company Profile

Novus Therapeutics, Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. Its lead product is a nasally-administered combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply